Roche’s cobas SARS-CoV-2 Test Receives the US FDA’s Emergency Use Authorization to Identify Corona Virus

Shots:

• The US FDA has issued a EUA for Roche’s cobas SARS-CoV-2 test for the qualitative detection of SARS-CoV-2, in nasopharyngeal and oropharyngeal swab samples taken from patients who meet COVID-19 clinical/ epidemiological criteria for testing
• The CE-IVD test is available in markets accepting the CE mark for patients with signs and symptoms of COVID-19. The CE mark and FDA’s EUA allow patients to access the diagnostic test to combat the disease
• The cobas SARS-CoV-2 test can be run on Roche’s cobas 6800/ 8800 systems and provide results in 3.5hrs., offering operating efficiency & fastest time-to-results with the highest throughput providing ~96 results in ~3hrs. and a total of 1,440 results for the cobas 6800 system and 4,128 results for the cobas 8800 system in 24hrs.

Click here ­to­ read full press release/ article | Ref: Roche  | Image: Pinterest